SCHEMBL4359150

SCHEMBL4359150

COc1ccc(C(NCCOC(=O)NCCCCCCO)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
KIF11 P52732 1/20 0.44
ACHE P22303 6/20 0.42
KMT2A Q03164 3/20 0.42
GAA P10253 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
LMNA P02545 2/20 0.40
TP53 P04637 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
NAMPT P43490 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
GLA P06280 1/20 0.39
ALDH1A1 P00352 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15841351 0.85 ACHE (0.41) ACHEALDH1A1TDP1
SCHEMBL10309879 0.85 KIF11 (0.45) NPC1RAB9AKIF11KMT2ALMNA
SCHEMBL6302955 0.85 KIF11 (0.45) NPC1RAB9AKIF11KMT2ALMNA
SCHEMBL8053146 0.85 KIF11 (0.45) NPC1RAB9AKIF11KMT2ALMNA
SCHEMBL4370978 0.83 NPC1 (0.41) NPC1RAB9AKIF11KMT2AGAA
SCHEMBL4364314 0.82 NPC1 (0.43) NPC1RAB9AKIF11KMT2AGAA
SCHEMBL9439820 0.80 KIF11 (0.47) KIF11KMT2ALMNASIGMAR1SMN1; SMN2
SCHEMBL888258 0.79 KIF11 (0.44) NPC1RAB9AKIF11KMT2ALMNA
SCHEMBL5384747 0.79 NPC1 (0.38) NPC1RAB9AKIF11KMT2AGAA
SCHEMBL12225852 0.78 KIF11 (0.49) KIF11KMT2AGAALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2749566-B1 SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE AIST (JP) 2018-05-09 EP disclosed
US-9428809-B2 Solid-phase carrier for aminated oligonucleotide NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2016-08-30 US disclosed
US-20140187724-A1 SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2014-07-03 US disclosed
EP-2749566-A1 SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE National Institute of Advanced Industrial Science And Technology (JP) 2014-07-02 EP disclosed
EP-1908829-B1 OLIGONUCLEOTIDE PROBE NAT INST OF ADVANCED IND SCIEN (JP) 2014-01-08 EP disclosed
US-7491857-B2 Oligonucleotide probe NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2009-02-17 US disclosed
US-20080227968-A1 Oligonucleotide Probe NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2008-09-18 US disclosed
EP-1908829-A1 OLIGONUCLEOTIDE PROBE National Institute of Advanced Industrial Science and Technology (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227968-A1 Oligonucleotide Probe APEX1, RNGTT, RNASEH1 NPC1 3238/4885RAB9A 4788/4885KIF11 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.